SAN DIEGO, Dec. 10 /PRNewswire/ -- ChemDiv, Inc., a leading chemistry-driven global contract research organization, has announced today the signing of a collaborative discovery research agreement with Siwa Biotech Corporation, Oklahoma City, OK. Under the agreement, ChemDiv will be initiating a high-throughput screen for small molecule inhibitors of tyrosylprotein sulfotransferases. The collaboration provides Siwa Biotech with access to ChemDiv's expertise in chemistry systems and lead discovery. Financial terms of the collaboration were not disclosed.
"We are pleased that such a dynamic company as Siwa Biotech chose to work with ChemDiv team on this research program," said Dr. Ilya Okun, Vice President Biology and Chief Technology Officer at ChemDiv, Inc. "Over the years we have been continuously building upon our integrated services platform to provide our valued customers with strong and efficient support for all of their discovery and development needs."
"We are excited to initiate this collaborative discovery project with ChemDiv. The project has an excellent chance of success, based on ChemDiv's excellent track record in small molecule drug discovery," said Kevin L. Moore, M.D., President Siwa Biotech Corporation.
About ChemDiv, Inc.:
ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract research organization delivering discovery opportunities and services for life science partners. ChemDiv is merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. Drawing on a long heritage in small-molecule chemistry research, a dedicated and personal approach to collaborative research and development as well as world class personnel and physical resources, ChemDiv provides partners with access to Discovery outSource(TM) a full service drug discovery offering encompassing synthetic chemistry; medicinal chemistry, diverse & focused screening libraries, global logistics and lead discovery. http://www.chemdiv.com
About Siwa Biotech Corporation:
Siwa Biotech Corporation is a start-up biotech company that was founded in late 2005. The company seeks to exploit its extensive portfolio of issued patents and proprietary knowledge about protein-tyrosine sulfation in order to develop treatments for serious diseases. Siwa is investigating the modulation of protein-tyrosine sulfation to treat a variety of diseases with unmet medical needs.
CONTACT: Ronald Demuth, General Manager of ChemDiv, Inc., +1-858-794-4860,
fax, +1-858-794-4931, email@example.com
Web site: http://www.chemdiv.com/